-transparent.png){kind=logo}
A method of measuring carbamazepine-10,11-epoxide (CBZ-10,11-EPOX) has been developed and used to monitor plasma concentrations in children suffering from various forms of epilepsy. Children stabilised on standard doses of CBZ alone showed a ratio of CBZ-10,11-EPOX/CBZ of 18.92 +/- 8.08, expressed as a percentage of the CBZ concentration, while those on multiple-drug therapy (with the exception of benzodiazepines and phenobarbitone) showed both increased values of CBZ-10,11-EPOX/CBZ ratio and increased absolute concentrations of CBZ-10,11-EPOX in plasma. These changes correlated with clinical side-effects which could not be attributed to CBZ itself or to the other drugs administered concurrently.
J F Schoeman, and
A A Elyas, and
E M Brett, and
P T Lascelles
December 1984,
British journal of clinical pharmacology,
J F Schoeman, and
A A Elyas, and
E M Brett, and
P T Lascelles
December 1998,
Therapeutic drug monitoring,
J F Schoeman, and
A A Elyas, and
E M Brett, and
P T Lascelles
January 2015,
Case reports in medicine,
J F Schoeman, and
A A Elyas, and
E M Brett, and
P T Lascelles
April 1992,
Epilepsy research,
J F Schoeman, and
A A Elyas, and
E M Brett, and
P T Lascelles
March 1985,
The Journal of pediatrics,
J F Schoeman, and
A A Elyas, and
E M Brett, and
P T Lascelles
October 1986,
Revista clinica espanola,
J F Schoeman, and
A A Elyas, and
E M Brett, and
P T Lascelles
February 1995,
Therapeutic drug monitoring,
J F Schoeman, and
A A Elyas, and
E M Brett, and
P T Lascelles
March 1976,
European journal of clinical pharmacology,
J F Schoeman, and
A A Elyas, and
E M Brett, and
P T Lascelles
January 1989,
Epilepsy research,
J F Schoeman, and
A A Elyas, and
E M Brett, and
P T Lascelles
March 1976,
Clinical pharmacology and therapeutics,
